UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 15, 2010 (January 14, 2010)
King Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Tennessee
|
|
001-15875
|
|
54-1684963 |
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.) |
|
|
|
501 Fifth Street, Bristol, Tennessee
|
|
37620 |
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (423) 989-8000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
King Pharmaceuticals, Inc. (the Company) is conducting a review of the potential value of its
Animal Health business in the context of the Companys overall strategic position and objectives,
and it has retained advisors to assist it in this effort. The Company has made no decisions that
would alter the current status of this business within the Companys operations.